We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
-1.15%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.35B
AUM Growth
-$748M
(-24%)
Cap. Flow
-$294M
Cap. Flow
% of AUM
-12.51%
Top 10 Holdings %
Top 10 Hldgs %
32.94%
Holding
108
New
18
Increased
28
Reduced
25
Closed
23
Avg Time Held Equity + Options
1
year
Top 10 Avg Time Held Equity + Options
0.4
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perspective Therapeutics
CATX
|
+$43.9M |
| 2 |
Cullinan Oncology
CGEM
|
+$33.2M |
| 3 |
Incyte
INCY
|
+$30M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$24.9M |
| 5 |
argenx
ARGX
|
+$23.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$139M |
| 2 |
Align Technology
ALGN
|
+$62M |
| 3 |
Boston Scientific
BSX
|
+$57.5M |
| 4 |
Eli Lilly
LLY
|
+$54.5M |
| 5 |
Alpine Immune Sciences Inc
ALPN
|
+$46.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.8% |
| 2 | Technology | 0.2% |
| 3 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Phathom Pharmaceuticals
PHAT
$560M
| $16.7M | 0.71% |
1,620,000
-115,000
| -7% | -$1.18M |
2021 Q4
10 quarters
|
|
52
AstraZeneca
AZN
$257B
| $16M | 0.68% |
102,500
+22,500
| +28% | +$3.39M |
2024 Q1
1 quarter
|
|
53
Keros Therapeutics
KROS
$211M
| $15.7M | 0.67% |
343,200
+133,500
| +64% | +$7.17M |
2024 Q1
1 quarter
|
|
54
Biohaven
BHVN
$1.63B
| $15.6M | 0.66% |
450,000
+375,000
| +500% | +$14.8M |
2022 Q4
6 quarters
|
|
55
Sanofi
SNY
$97.3B
| $15.3M | 0.65% |
+315,000
| New | +$15.2M |
2024 Q2
0 quarters
|
|
56
Regenxbio
RGNX
$457M
| $15.2M | 0.65% |
1,300,064
| – | – |
2024 Q1
1 quarter
|
|
57
Context Therapeutics
CNTX
$22.4M
| $14.9M | 0.63% |
+7,419,355
| New | +$12.8M |
2024 Q2
0 quarters
|
|
58
DELISTED
Exact Sciences
EXAS
| $14.3M | 0.61% |
+338,500
| New | +$18.6M |
2024 Q2
0 quarters
|
|
59
Privia Health
PRVA
$2.88B
| $13.3M | 0.56% |
764,200
| – | – |
2023 Q2
4 quarters
|
|
60
NewAmsterdam Pharma
NAMS
$2.37B
| $10.7M | 0.46% |
559,300
+84,300
| +18% | +$1.69M |
2024 Q1
1 quarter
|
|
61
Immunome
IMNM
$1.94B
| $10.6M | 0.45% |
873,891
| – | – |
2023 Q4
2 quarters
|
|
62
Immunic
IMUX
$95.1M
| $9.88M | 0.42% |
890,297
| – | – |
2024 Q1
1 quarter
|
|
63
Corbus Pharmaceuticals
CRBP
$87.4M
| $9.76M | 0.41% |
+215,600
| New | +$9.07M |
2024 Q2
0 quarters
|
|
|
HELP
64
Helus Pharma Inc. Common Stock
HELP
$771M
| $9.45M | 0.4% |
918,000
| – | – |
2024 Q1
1 quarter
|
|
65
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $8.64M | 0.37% |
1,673,538
| – | – |
2022 Q3
7 quarters
|
|
66
Cogent Biosciences
COGT
$5.12B
| $8.44M | 0.36% |
1,000,706
+555,000
| +125% | +$4.21M |
2024 Q1
1 quarter
|
|
67
Immunocore
IMCR
$1.51B
| $6.78M | 0.29% |
200,000
-86,400
| -30% | -$4.41M |
2021 Q1
13 quarters
|
|
68
Tyra Biosciences
TYRA
$1.27B
| $5.96M | 0.25% |
+373,000
| New | +$6.42M |
2024 Q2
0 quarters
|
|
69
UiPath
PATH
$6.7B
| $4.59M | 0.2% |
+362,000
| New | +$6.26M |
2024 Q2
0 quarters
|
|
70
Spyre Therapeutics
SYRE
$7.47B
| $4.58M | 0.19% |
+195,000
| New | +$6.58M |
2024 Q2
0 quarters
|
|
71
Immatics
IMTX
$1.02B
| $4.57M | 0.19% |
+393,100
| New | +$4.43M |
2024 Q2
0 quarters
|
|
72
Ionis Pharmaceuticals
IONS
$7.14B
| $4.43M | 0.19% |
93,000
-37,000
| -28% | -$1.52M |
2024 Q1
1 quarter
|
|
73
Oruka Therapeutics
ORKA
$4.76B
| $3.83M | 0.16% |
+83,333
| New | +$3.32M |
2024 Q2
0 quarters
|
|
74
Editas Medicine
EDIT
$361M
| $3.81M | 0.16% |
+816,000
| New | +$4.6M |
2024 Q2
0 quarters
|
|
75
Intellia Therapeutics
NTLA
$1.6B
| $3.8M | 0.16% |
+170,000
| New | +$4.05M |
2024 Q2
0 quarters
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q2 2024 Portfolio in Review
As of Q2 2024, Avidity Partners Management held 108 positions worth $2.35B, down 24% from $3.1B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Avidity Partners Management withdrew a net $294M in Q2 2024, closing 23 positions and reducing 25 holdings. Its most notable exit was Fusion Pharmaceuticals Inc. Common Shares, an estimated $139M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Technology and Miscellaneous.
Against the trend, Avidity Partners Management opened a new position in Perspective Therapeutics worth $30.3M.
- Avidity Partners Management's largest Q2 2024 buy was Perspective Therapeutics: 3,037,668 shares worth $30.3M.
- Avidity Partners Management added most to Thermo Fisher Scientific in Q2 2024, an estimated $24.9M increase.
- Avidity Partners Management's biggest Q2 2024 reduction was Boston Scientific, cutting an estimated $57.5M.
- Avidity Partners Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $139M.
- Avidity Partners Management's ten largest holdings make up 33% of its $2.35B portfolio in Q2 2024.
- Avidity Partners Management opened 18 new positions and closed 23 in Q2 2024.
- Avidity Partners Management's portfolio value fell 24% quarter-over-quarter to $2.35B.
Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.